Results from ImagistxProstate™ Ultra High Resolution Ultrasound Study at Johns Hopkins Hospital Show Significant Increase in Prostate Cancer Detection

Share Article

Imagistx, Inc. announces the interim results of a study conducted by Christian Pavlovich, MD at the Brady Urological Institute at Johns Hopkins Hospital. The results were highlighted at the recent 12th Annual Meeting of the Society of Urologic Oncology in Bethesda, MD.

The poster presented “Ultra High-Resolution Transrectal Ultrasound: A Novel Technique for Enhanced Prostate Cancer Imaging” was designed to compare the differences between Ultra High Resolution (UHR) and Low Resolution (LR) transrectal ultrasound in their ability to detect cancerous foci in 20 patients. Results showed significant increases in Sensitivity (56.5%), Specificity (21.1%) and PPV (42.0%) with ImagistxProstate™ Ultra High Resolution (UHR) ultrasound versus Low Resolution (LR) ultrasound. A copy may be found at http://www.ImagistxProstate.com.

Dr. Pavlovich, the study’s Principal Investigator, noted, “Prostate cancer is the only solid malignancy for which no reliable imaging modality exists for the detection of localized disease. UHR-TRUS is a safe and promising imaging modality for prostate cancer detection and has shown to be superior to LR-TRUS in the identification of cancerous foci.”

The IRB-approved study was designed to prospectively recruit 25 men with biopsy-proven prostate cancer who were scheduled for radical prostatectomy (RP). Patients were imaged pre-operatively with both UHR-TRUS and LR-TRUS. Areas of altered echogenicity ≥ 5mm on sagittal views were identified by a radiologist with an expertise in ultrasound blinded to pathology results. Actual areas of prostate cancer ≥5mm identified at sagitally-sectioned RP specimen were correlated to abnormal foci on both imaging modalities. Sensitivity and specificity analysis were performed for each imaging modality. A total of 56 cancerous foci were pathologically identified. UHR-TRUS was superior to LR-TRUS in the identification of these foci (p = 0.01).

Tom Dempsey, Imagistx President & CEO, stated, “We are highly encouraged by the interim results of the study. The system has performed with consistent reliability and has shown to potentially be of great use to practitioners and patients alike in the detection of prostate cancer. We look forward to the completion of the study this January.”

About ImagistxProstate™
Imagistx’ proprietary technology addresses the limitations of current prostate imaging systems by providing a unique high resolution image for the screening, detection, biopsy and potential treatment of prostate cancer. The ImagistxProstate® ultrasound system operates at 21 MHz center frequency; combining high resolution, 3D images with 3D reconstruction to detect and target for biopsy and future focal therapy applications for prostate cancer. The FDA has not approved this device for commercial distribution.

About Imagistx, Inc.
Imagistx, Inc. is a privately held company with operations in the U.S. and Canada. The product pipeline is focused on the development of UHR ultrasound systems for the detection of prostate cancer.

About Johns Hopkins Hospital
The Johns Hopkins Hospital and The Brady Urological Institute have been ranked the #1 hospital and Urology Department in America by U.S. News & World Report (most recent 2011) for 21 consecutive years. Please visit: http://www.urology.jhu.edu.

Contact:
Tom Dempsey
Imagistx, Inc.
(303) 888-4266
http://www.imagistxprostate.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Dempsey